Background Studies have suggested an inverse association between coffee consumption and risk of renal cell carcinoma (RCC); however, data regarding decaffeinated coffee are limited. Methods We conducted a case-control study of 669 incident RCC cases and 1,001 frequency-matched controls. Participants completed identical risk factor questionnaires that solicited information about usual coffee consumption habits. The study participants were categorized as noncoffee, caffeinated coffee, decaffeinated coffee, or both caffeinated and decaffeinated coffee drinkers. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated using logistic regression, adjusting for multiple risk factors for RCC. Results Compared with no coffee consumption, we found an inverse association between caffeinated coffee consumption and RCC risk (OR 0.74; 95% CI 0.57-0.99), whereas we observed a trend toward increased risk of RCC for consumption of decaffeinated coffee (OR 1.47; 95% CI 0.98-2.19). Decaffeinated coffee consumption was associated also with increased risk of the clear cell RCC (ccRCC) subtype, particularly the aggressive form of ccRCC (OR 1.80; 95% CI 1.01-3.22). Conclusions Consumption of caffeinated coffee is associated with reduced risk of RCC, while decaffeinated coffee consumption is associated with an increase in risk of aggressive ccRCC. Further inquiry is warranted in large prospective studies and should include assessment of doseresponse associations.
Introduction
Incidence rates for renal cell carcinoma (RCC) have been rising over the last several decades, while mortality rates have remained fairly stable [1] [2] [3] . The etiology of RCC is not completely understood and while understanding the underlying biology of RCC remains an area of active inquiry, there is a pressing need to work in parallel to identify modifiable risk factors to better inform strategies for prevention of this increasingly common malignancy. Few modifiable predisposing factors for RCC have been well-established, namely cigarette smoking, obesity, and hypertension; however, these factors have been reported to account for only about one-half of all RCC cases diagnosed each year in the United States [4, 5] . Further research is therefore needed to identify additional contributing risk factors for RCC cases, particularly modifiable risk factors for the most aggressive forms of RCC.
Based on suggestions that caffeine or other antioxidants in coffee (e.g., phenolic acids [6] ) may reduce cancer risk, several groups have examined the association between coffee consumption and RCC risk, with varying results [7] [8] [9] [10] [11] [12] [13] [14] . These mixed findings may be due, in part, to the inability of investigators to separate caffeinated coffee from decaffeinated coffee consumption, which are thought to have varying health effects because of differing levels of caffeine, and possibly other antioxidants [15, 16] . There is also a longstanding hypothesis that historical methods used for decaffeinating coffee (i.e., exposing coffee beans to a variety of chemical solvents) may have detrimental health effects [17, 18] .
The largest study on coffee consumption and RCC risk conducted to date, a pooled analysis of 13 prospective studies, reported that overall coffee consumption was associated with a modest reduction in RCC risk [19] . However, the true association appeared to have been masked in that study by the mixing of caffeinated and decaffeinated coffee consumption into one group [19] . More recently, a case-control study conducted in Italy reported a null association between overall coffee consumption and RCC risk, but the investigators observed a suggestion of an increase in RCC risk associated with decaffeinated coffee consumption (odds ratio [OR] = 1.38, 95% confidence interval [CI] = 0.94-2.03, coffee drinker vs. non-drinkers) [20] . Due to the absence of a centralized pathology review, they were unable to explore associations with specific histologic subtypes of RCC or with the more aggressive forms of RCC. Therefore, we analyzed data from a large case-control study to determine the relationship between decaffeinated and caffeinated coffee consumption and RCC risk. We further investigated associations of decaffeinated and caffeinated coffee intake with the clear cell subtype of RCC [5] . In addition, we examined associations between these forms of coffee consumption and several known and accepted prognostic factors for cancer-specific death from clear cell RCC (ccRCC), as determined by the externally validated, Mayo Clinic SSIGN (tumor stage, size nuclear grade, and necrosis) scoring algorithm [21] [22] [23] .
Methods

Cases and controls ascertainment
Following Mayo Clinic Institutional Review Board approval, we ascertained RCC cases from the Renal Cancer Registry, housed in the Departments of Urology at Mayo Clinic in Rochester, MN, and Mayo Clinic in Jacksonville, FL. As part of the Registry efforts, patients undergoing surgery for newly diagnosed, clinically localized RCC provide written informed consent for data and specimen collection. This study utilized the registry databases to identify RCC patients treated at each of the two sites between May 2003 and July 2012, who have completed risk factor questionnaire at enrollment. At each site, approximately 70% of RCC patients consented and completed the risk factor questionnaires. Non-cancer control patients were recruited from each site using site-specific resources.
In Jacksonville (FL), controls were identified through review of appointment calendars of the Department of Family and Community Medicine ahead of patient visit for a regular wellness check-up. Potential control patients were approached on their appointment dates for recruitment and asked to complete risk factor questionnaires identical to those completed by the RCC cases. Among the potential controls approached, 73% completed and returned the questionnaires. The cases and controls in Jacksonville completed the risk factor questionnaires at enrollment. The Jacksonville controls were frequency-matched to the Jacksonville cases on age (±5-years), sex, and state of residence. In Rochester (MN), controls were recruited through collaboration with the Mayo Clinic Biobank [24] . In brief, Mayo Clinic patients who were (1) 18 years or older, (2) of sound mind and memory and able to consent, and (3) US residents were eligible to participate in the Mayo Clinic Biobank in Rochester. Individuals recruited to the Biobank were asked to complete a health history questionnaire and to provide consent for future contact for additional data collection. We leveraged this resource by pooling a random sample of potential controls from the Biobank who reported no personal history of kidney cancer. The potential controls were mailed the same risk factor questions completed by the cases to obtain information that was not originally collected as part of the Biobank health history questionnaire (i.e., history of alcohol and coffee consumption). Of the potential Biobank controls invited to participate, 76% completed and returned the risk factor questionnaires. The Rochester controls also were frequency-matched to the Rochester cases on age (±5 years), sex, and state of residence.
Centralized pathology review on RCC cases
As part of the Registry efforts at both Rochester and Jacksonville, H&E slides from RCC patients undergo a centralized pathology review by genitourinary pathologists from our investigative team (J.C.C. and K.J.W.). This process establishes the diagnosis of RCC, verifies the histological subtype (e.g., clear cell or papillary), and provides confirmation of tumor stage, size, nuclear grade and necrosis-the components of the SSIGN scoring algorithm [21] . In brief, the Mayo Clinic SSIGN score is an externally validated [22, 23] scoring system that is used clinically to determine which ccRCC patients are at greater risk of dying from the disease after surgical excision of the primary tumor. In this study, the SSIGN scores were used to categorize ccRCC patients as having less aggressive or moderate/high aggressive disease, as described below.
Assessment of coffee intake and covariates
The RCC cases and controls completed a self-administered, identical risk factor questionnaire that solicited information on a variety of environmental and lifestyle risk factors, including usually intake of caffeinated and decaffeinated coffee (i.e., cups per day). The same questions were used to solicit information on coffee consumption at each site for both cases and controls. The questionnaire asked participants, ''how often have you usually drank coffee as an adult (18 years old or older), please exclude dietary changes within the last two years.'' Response options included usual number of cups consumed per day of caffeinated coffee, decaffeinated coffee, both, or rarely/never.
To maximize sample sizes for coffee consumption categories, information on cups per day were used to categorize participants into four groups: non-coffee drinkers, regular consumers of caffeinated coffee only, regular consumers of decaffeinated coffee only, or both. Other information obtained from the risk factor questionnaire included demographics (age, sex, race/ethnicity, marital status, and the highest level of education), smoking history, adult height, usual adult weight, self-reported history of hypertension, and alcohol consumption habits. Data on usual adult weight and height collected at enrollment were used to calculate body mass index (BMI) as the ratio of weight to height in kilograms per meter squared (kg/m 2 ). Smoking history was categorized as never, former, and current. Data on coffee consumption and covariates were available for 669 RCC cases and 1,001 controls (Supplementary Table 1 ).
Statistical analysis
Means and proportions were used to compare demographic, lifestyle, and anthropometric measures between cases and controls. Unconditional logistic regression was used to calculate ORs and 95% CIs. In examining the association between coffee consumption and RCC risk, non-coffee drinkers were used as the referent group to estimate ORs and 95% CIs for the other coffee consumption categories, adjusting for various known risk factors for RCC. The most comprehensively adjusted (i.e., fully adjusted) model included age (continuous), sex, institutional site (Jacksonville, Rochester), smoking history (never, former, current), BMI (continuous), self-reported history of hypertension (no, yes) and alcohol consumption (never, ever) to account for potential confounding by these factors. To examine whether the association between coffee consumption and RCC is modulated by known risk factors for RCC, we performed stratified analyses by age (\64 vs. C64 years; the median age among controls), sex, BMI (\30 vs. C30 kg/m 2 ), smoking history [ever (former ? current), never], history of hypertension (yes, no), alcohol consumption (yes, no), and study site (Rochester vs. Jacksonville) in fully adjusted models. We further examined interaction between each of these factors and the coffee consumption variable using likelihood ratio Chi-square test nested in multivariable-adjusted logistic regression models with and without multiplicative interaction terms (i.e., age group 9 coffee consumption). In assessing interaction, Chi-square tests were used to determine statistical significance of difference between -2 loglikelihood values from the full model (with interaction) and the reduced model using appropriate degrees of freedom (i.e., difference in degrees of freedom between the two models).
Because of the heterogeneous nature of RCC, we performed separate analyses between coffee consumption and ccRCC; the most common subtype ([80% of all RCC) [25] . Among the 669 RCC cases included the study, 516 were determined through the centralized pathologic review as ccRCC. We compared these ccRCC cases with the same set of controls used in the larger analysis (n = 1, 001). Further, we explored associations of coffee consumption with the extent of ccRCC aggressiveness. The Mayo Clinic SSIGN score was used to classify the ccRCC cases into low aggressive (SSIGN score 0-3) and moderate or high aggressive (SSIGN score C4) disease groups [21] and exploratory analyses were performed using polychotomous logistic regression. All statistical tests herein reported were two-sided and p values lower than 0.05 were considered statistically significant. Analyses were performed using SAS Ò version 9.3 (SAS Institute, Cary, NC, USA).
Results
Characteristics of the 669 RCC cases and 1,001 controls included in the study are presented in Table 1 . Given the frequency-matched design, the cases and controls did not differ by age or sex and were similar in self-identified race and marital status. Compared to controls, cases were less likely to have college or graduate level education (54 vs. 36%). A greater proportion of cases than controls had a BMI [30 kg/m 2 (56 vs. 46%), and the cases were also more likely than controls to reported being a current smoker (7 vs. 3%), report a personal history of hypertension (62 vs. 46%) or reported never consuming alcohol (20 vs. 15%). While the proportion of caffeinated coffee only drinkers was higher among controls than cases (53 vs. 45%), there was a slightly higher proportion of decaffeinated coffee only drinkers among cases than controls (13 vs. 8%). Differences in age, institutional site, race, smoking history, history of hypertension, and alcohol consumption were observed between the four coffee exposure groups (i.e., non-drinkers, caffeinated coffee drinks, non-caffeinated coffee drinks, and both) (Supplementary Table 2) . Table 2 shows results for associations between coffee consumption and RCC risk. In the age-adjusted model, regular consumption of caffeinated coffee was associated with a 27% reduced risk of RCC (OR 0.73, 95% CI 0.58-0.93), whereas regular consumption of decaffeinated coffee was associated with a 50% increase in risk of RCC (OR 1.50, 95% CI 1.04-2.17), compared with non-coffee consumption. After adjusting for age, institutional site, sex, smoking, BMI, hypertension, and alcohol consumption, caffeinated coffee consumption remained inversely associated with RCC risk (OR 0.74, 95% CI 0.57-0.97) and decaffeinated coffee consumption remained positively related to RCC risk (OR 1.48, 95% CI 0.99-2.21). Of note, we did not observe significant associations in the age-or multivariable-adjusted models for consumption of both caffeinated and decaffeinated coffee, which reflects the masking of associations in studies that combined caffeinated with decaffeinated coffee (Table 2) .
In Table 3 , we present results of analyses stratified by known risk factors for RCC. There was a consistent pattern of lower ORs for RCC risk with caffeinated coffee consumption and elevated ORs for decaffeinated coffee consumption both among individuals \64 years and those C64 years. No statistically significant interaction was observed by sex, BMI category, smoking status, or study site. However, compared to non-coffee drinkers, decaffeinated coffee consumption was associated with increased RCC risk among females (OR 2.19, 95% CI 1.16-4.13) and among never smokers (OR 1.83, 95% CI 1.06-3.15), whereas caffeinated coffee was associated with decreased RCC risk among individuals with BMI C30 kg/m 2 (OR 0.67, 95% CI 0.46-0.94) and among ever smokers (OR 0.61, 95% CI 0.40-0.94). Significant interactions were observed by alcohol consumption and history of hypertension (interaction p values \0.001), such that among non-alcohol users, caffeinated coffee was associated with decreased RCC risk (OR 0.44, 95% CI 0.23-0.83), while decaffeinated coffee consumption was associated with increased risk (OR 3.72, 95% CI 1.49-9.29). Among individuals both with and without a personal history of hypertension, there was a suggestion of lower RCC risk associated with caffeinated coffee intake, whereas there was a trend toward increased risk associated with decaffeinated coffee intake. Table 4 shows results from analyses that limited the RCC cases to those with the clear cell subtype (ccRCC). In fully adjusted models, ORs for ccRCC risk associated with caffeinated coffee and decaffeinated coffee consumption were 0.77 (95% CI 0.58-1.02) and 1.40 (95% CI 0.90-2.17), respectively, compared with no coffee consumption. Results from the exploratory polychotomous regression analyses showed some interesting associations with the extent of ccRCC aggressiveness (Table 4) . Compared with no coffee consumption, caffeinated coffee intake was associated with reduced risk of the less aggressive form of ccRCC (OR 0.62, 95% CI 0.44-0.88), and no association was observed between decaffeinated coffee and less aggressive ccRCC. In contrast, decaffeinated coffee consumption was associated with higher risk of the moderate or high aggressive forms of ccRCC (OR 1.80, 95% CI 1.01-3.22), and no association was observed with caffeinated coffee consumption. As with the overall RCC risk, no association was observed between consumption of both caffeinated and decaffeinated coffee with ccRCC or the extent of ccRCC aggressiveness. 
Discussion
In this large case-control study, we observed an inverse association between caffeinated coffee intake and RCC risk. Our results also suggest a positive association between decaffeinated coffee consumption and RCC risk. The increased RCC risk associated with decaffeinated coffee consumption was most pronounced among females, never smokers, and non-alcohol users. For the clear cell subtype of RCC, there were suggestions of an increased risk associated with decaffeinated coffee and decreased risk associated with caffeinated coffee consumption. We further found that decaffeinated coffee consumption was associated with an increase in risk of the moderate or highly aggressive form of ccRCC, whereas caffeinated coffee consumption was associated with lower risk of the less aggressive form of ccRCC. Together, these findings suggest that caffeinated coffee intake may play a protective role against RCC development, while regular consumption of decaffeinated coffee may increase RCC risk. Because of the kidney's function as the body's primary filtration system, several investigators have examined the hypothesis that consumption of certain fluids and their subsequent clearance by the kidney may be associated with RCC risk [5] . In this context, overall coffee consumption has been examined in relation to RCC in many studies [7] [8] [9] [10] [11] [12] [13] [14] ; however, the possibility that the effect of decaffeinated coffee may differ from that of caffeinated coffee has not been investigated thoroughly. In 2007, Lee et al. provided the most definitive evaluation of overall coffee consumption (caffeinated and decaffeinated combined) and RCC risk to date [19] . Their pooled analysis of 13 prospective studies, reported that consumption of [ 3 cups of coffee per day (compared to \1 per day) is associated with a modestly lower risk of RCC (pooled RR = 0.84; p = 0.22), particularly among women (pooled RR = 0.71; p = 0.07) [19] . These authors proposed explanations that centered on improved insulin sensitivity and lower C-peptide levels for coffee drinkers [26] [27] [28] and antioxidant effects of caffeine [29, 30] . For the gender-specific effect, the authors noted published evidence of differences in metabolism of caffeine between men and women [31] . Germane to the present study, Lee et al. could not evaluate the risk associated with caffeinated and decaffeinated coffee separately because of data limitations [19] . We are aware of only one other study that reported evidence of a possible association of decaffeinated coffee and RCC risk. [20] . Given the relatively novel nature of the finding and the lack of a statistical significance, the authors did not conduct further exploration analyses (e.g., stratified analyses) or comment on potential mechanisms supporting this putative association. The current study is, therefore, the first study to provide more compelling evidence that decaffeinated coffee consumption increases RCC risk. While we cannot completely rule out the role of chance or bias as a possible explanation for the association with decaffeinated coffee, it is worth noting that historical methods of decaffeinating coffee involved exposure of coffee beans to a variety of toxic solvents (e.g., benzene, chloroform, dichloromethane, ethyl acetate, methylene chloride) [15, 17] . Therefore, it is reasonable to suggest that residual chemicals could be ingested from the consumption of decaffeinated coffee and that kidney would be at specific risk of any possible carcinogenic effects of these chemicals given its function as the primary fluids filtration organ of the body. Another explanation could be an indirect effect, in that, antioxidant contents of decaffeinated coffee have been reported to be generally lower than that of caffeinated coffee [15, 16] . Further, habitual decaffeinated coffee consumers would potentially not benefit from the improved insulin sensitivity or lower C-peptide levels that have been associated with caffeinated coffee consumption [26] [27] [28] and suggested to offer some protection against RCC [19] . These explanations require further verification in studies that would account for means of caffeine consumption (e.g., tea, energy drinks, etc.) and dose-response associations. Moreover, the observed interactions, particularly with sex, alcohol consumption, and hypertension may be too preliminary to definitive conclusions to be drawn. Further investigations are needed to validate our findings and unravel the mechanisms underlying the observed associations.
Limitations of the present study included those inherent to all case-controls studies, such as recall and participation biases. Differential recall between cases and controls, wherein cases had better recall of coffee drinking habits than controls, could either inflate or attenuate the true associations. However, because of lack of widespread public knowledge of the association between coffee consumption and RCC risk, it is less likely that the cases considered their diagnosis or the extent of the disease aggressiveness when responding to questions about coffee intake. Non-differential recall of coffee consumption among cases and controls is more likely to have occurred, which generally tends to attenuate effect estimates. Nevertheless, we noticed that questions about decaffeinated coffee were not answered by more of the cases than controls (33 vs. 11%) and we presume that those who skipped questions about decaffeinated coffee drinking habits did so because they did not drink this type of coffee. If true, we would have underrepresented the percentage of ''never'' coffee consumers in the cases and this would have led to an overestimation of the ORs. However, because we are unable to assign a specific reason why some subjects skipped questions on decaffeinated coffee and it is unlikely that all of these subjects would be non-decaffeinated coffee users, we restricted the analysis to those with complete information on coffee consumption. Other limitations include limited generalizability of our findings given that our analytic sample consisted predominantly of self-identified Caucasians ([90%) recruited from a tertiary referral center. Furthermore, we were unable to assess quantity of intake and therefore restricted analyses to drinkers of different coffee types versus non-drinkers. Residual confounding by poorly measured factors or confounding by unmeasured factors cannot be ruled out. Moreover, selfreported coffee intake may not necessarily reflect bioavailable levels of caffeine or constituents of coffee owing to individual differences in metabolisms and absorption. Strengths of the study include its large size, the centralized pathology review of malignancy among cases, availability of data on multiple confounders, and the ability to explore associations with the aggressive forms of RCC using a clinically validated scoring algorithm for RCC prognosis (i.e., the Mayo clinic SSIGN score).
The results of the present study suggest that caffeinated coffee consumption is associated with reduced risk of RCC, whereas consumption of decaffeinated coffee may increase RCC risk. Decaffeinated coffee consumption was associated also with increased risk of the aggressive forms of ccRCC. Further studies are needed to validate these findings and explore possible mechanisms underlying the associations, particularly the suggestive interactions with alcohol consumption and hypertension status. the article; final approval of the manuscript. NDD contributed in analysis and interpretation of data; final approval of the manuscript. DJS contributed in analysis and interpretation of data; final approval of the manuscript. KMC contributed in acquisition of data; final approval of the manuscript. MLA contributed in acquisition of data; final approval of the manuscript. KJW contributed in acquisition of data; final approval of the manuscript. JCC contributed in acquisition of data; final approval of the manuscript. DDT contributed in acquisition of data; final approval of the manuscript. BCL contributed in acquisition of data; final approval of the manuscript. ASP contributed in conception and design; analysis and interpretation of data; drafting the article; final approval of the manuscript.
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